Canaccord Genuity Initiates Coverage On Connect Biopharma Hldgs with Buy Rating, Announces Price Target of $6
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Canaccord Genuity analyst Edward Nash initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy rating and announces Price Target of $6.
Canaccord Genuity analyst Edward Nash initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy rating and announces Price Target of $6.